Why AstraZeneca's breast cancer drug has potential to redefine standard of care
- Strong efficacy for metastatic breast cancer treatment Enhertu- Reducing disease progression by 50% and death by 36%- Potential for $3 billion of additional salesPharmaceutical company AstraZeneca (AZN) announced its metastatic...
06 June 2022